Exploring Disparities and Novel Insights into Metabo-Nutritional Comorbidities among COVID-19 Patients in Mexico

During the previous years, particularly at the beginning of the COVID-19 pandemic, the potential role of metabo-nutritional comorbidities in the severity and lethality of SARS-CoV2 infection has been widely discussed, often describing ambiguous outcomes. Here we investigate the prevalence of metabo-nutritional comorbidities among COVID-19 patients in Mexico. Using a retrospective observational study design, data was collected from official databases of COVID-19 patients admitted to public and private hospitals in Mexico City. Our study found a discordant prevalence of metabo-nutritional comorbidities among COVID-19 patients, particularly obesity, hypertension, and diabetes. Discordance consists in geographic location-dependent over and under-representation phenomena, that is the prevalence of such comorbidities in COVID-19 patients was significantly over or under the reported value for the general population in each location. These findings highlight the importance of screening for metabo-nutritional comorbidities in COVID-19 patients and suggest the need for tailored interventions for this population. The study also provides insights into the complex relationships between COVID-19 and metabo-nutritional comorbidities, which may inform future research and clinical practice. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was partially funded using a grant from CONACYT (320557 2022 FOP16 21 01 CONACYT, to Guillermo de Anda Jauregui). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study used ONLY openly available human data that were originally located at: and I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present work are contained in the manuscript